Home | Welcome to Contract Pharma   
Last Updated Tuesday, May 21 2013
Print

Industry News

Related Searches:

Filter by:

Pfizer To Acquire Serenex
March 3, 2008
Pfizer has entered into an agreement to acquire Serenex, Inc., a privately-held biotechnology company with a Phase I clinical candidate and an extensive compound library that targets Heat Shock Protein 90 (Hsp90), an anti-cancer target.   …   Read More »
Crucell, Wyeth Enter Vaccine Development Pact
March 3, 2008
Crucell N.V. has entered into an exclusive vaccine development agreement with Wyeth Pharmaceuticals. Under the terms of the agreement, Crucell will be responsible for the development and manufacture of certain components of a vaccine for use in Wyeth…   Read More »
Baxter Adds To Heparin Recall
February 29, 2008
Baxter International is proceeding with the voluntary recall of all remaining lots and doses of its heparin sodium injection multi-dose, single-dose vials and HEP-LOCK heparin flush products. The company initially recalled nine lots of heparin sodium…   Read More »
DPT Adds Regulatory Prep Service
February 29, 2008
DPT Laboratories has added preparation of the chemistry, manufacturing and controls documents (CMC) in the Common Technical Documents (CTD) format as an optional service for customers applying for approval of new drugs. The new service provides pr…   Read More »
Cobra To Make SARS Protein
February 28, 2008
Cobra Biomanufacturing Plc has entered into a manufacturing development agreement with an undisclosed pharmaceutical partner to produce a protein from the SARS virus in CHO (Chinese Hamster Ovary) cells under cGMP. Simon Saxby, Cobra Biomanufactur…   Read More »
FDA Launches Drug Safety Effort
February 27, 2008
The FDA is launching a new effort for post-approval drug safety, called "Safety First," meant to strengthen its supervision of prescription drugs after approval.     The plan, first reported by the Wall Street Journal and…   Read More »
Vetter Gets Production Approval From FDA
February 27, 2008
Vetter Pharma-Fertigung GmbH & Co. has been granted approval by the FDA for the production of a client's new drug. The company will begin filling the drug at its Ravensburg Vetter South (RVS) facility. Vetter provides contract manufacturing servi…   Read More »
Bayer Licenses Millipore Technology For Bio-Manufacturing
February 26, 2008
Bayer HealthCare AG has entered into a worldwide, non-exclusive license agreement with Millipore to use its UCOE (Ubiquitous Chromatin Opening Element) technology to manufacture its biologic drugs. The license will enable Bayer to manufacture recombi…   Read More »
United BioSource Expands Regulatory Affairs Group
February 25, 2008
United BioSource Corp. (UBC) has expanded its regulatory affairs group led by Mark Ammann, Pharm.D. and LaVonne Lang, Dr. PH. The group, based in Ann Arbor, MI, will provide a full range of services to pharma and biopharma clients, including creating…   Read More »
Azopharma Opens South Florida Facility
February 22, 2008
Azopharma Product Development Group, Inc. has opened a new facility in South Florida. The new 22,000-sq.-ft. facility will house the company’s formulation development services, small-scale manufacturing, development services and specialized ana…   Read More »
Genmab To Purchase Manufacturing Facility From PDL
February 21, 2008
Genmab and PDL BioPharma, Inc. have entered into an agreement under which Genmab will acquire PDL's antibody manufacturing facility in Brooklyn Park, MN, for $240 million in cash. The transaction includes land, equipment and access to a leased space…   Read More »
Pfizer To Acquire Encysive Pharmaceuticals
February 20, 2008
Pfizer has entered into an agreement to acquire Encysive Pharmaceuticals, Inc., a publicly held biopharma company, for an equity value of approximately $195 million. Pfizer will acquire the rights to Thelin, an oral, endothelin A receptor antagoni…   Read More »
GSK Licenses EUSA Antibody
February 19, 2008
GlaxoSmithKline has licensed exclusive world-wide rights to EUSA Pharma, Inc.'s preclinical human anti-interleukin-6 antibody for a consideration of as much as $44 million, which includes an upfront fee, development milestones and royalties on future…   Read More »
AstraZeneca Spins Off GI Research Operation
February 15, 2008
AstraZeneca has spun off part of its gastrointestinal research operation into a new biopharmaceutical company called Albireo. The move is part of the company's realignment plans, announced in 2006, to refocus its research away from certain areas with…   Read More »
Baxter Suspends Heparin Production
February 15, 2008
Baxter International, Inc. has temporarily suspended production of heparin, a blood-thinner, due to reports of allergic reactions, including four deaths, primarily in patients undergoing kidney dialysis and heart surgery. Heparin, a generic drug, is…   Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: